TY - JOUR
T1 - Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children
T2 - SpIDnet observational multicentre study
AU - Savulescu, Camelia
AU - Krizova, Pavla
AU - Valentiner-Branth, Palle
AU - Ladhani, Shamez
AU - Rinta-Kokko, Hanna
AU - Levy, Corinne
AU - Mereckiene, Jolita
AU - Knol, Mirjam
AU - Winje, Brita A.
AU - Ciruela, Pilar
AU - de Miguel, Sara
AU - Guevara, Marcela
AU - MacDonald, Laura
AU - Kozakova, Jana
AU - Slotved, Hans-Christian
AU - Fry, Norman K.
AU - Pekka Nuorti, J.
AU - Danis, Kostas
AU - Corcoran, Mary
AU - van der Ende, Arie
AU - Vestrheim, Didrik F.
AU - Munoz-Almagro, Carmen
AU - Sanz, Juan-Carlos
AU - Castilla, Jesus
AU - Smith, Andrew
AU - Colzani, Edoardo
AU - Pastore Celentano, Lucia
AU - SpIDnet VE study group
AU - Hanquet, Germaine
N1 - Funding Information: SpIDnet VE group: Zitta Harboe declare to have received a travel grant for participating in ECCMID (2019) from Pfizer. Emmanuelle Varon reports grants from French public health agency, during the conduct of the study; grants from Pfizer, grants from MSD, outside the submitted work. Hilary Humphreys reports research funds from Astellas and Pfizer and a professional fee from Pfizer. The funders had no role in the collection, analysis, interpretation of data or in the writing of any articles for publication. Zahin Amin-Chowdhury and Nick Andrews report providing vaccine manufacturers with post-marketing surveillance reports, which the companies are required to submit to the UK licensing authority in compliance with their risk management strategy. In accordance with UK Health Security Agency policy, a cost recovery charge is made for these reports payable to the Immunisation and Vaccine Preventable Diseases Division. Funding Information: This work was ideated and mainly funded by the European Centre for Disease Prevention and Control (project ECDC/2015/031). Surveillance data were collected using the ECDC-approved standard protocol. Pooled analysis was conducted at the co-ordination level. ECDC reviewed and approved the manuscript. The decision to submit for publication was made by consensus between the coordination team, surveillance sites and ECDC. The project received public funding only. Publisher Copyright: © 2022 Elsevier Ltd
PY - 2022/6/23
Y1 - 2022/6/23
N2 - Background: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010–11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). Methods: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012–2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. Results: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0–88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8–96.1) < 12 months to 85.1% (72.0–92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7–94.7) against fatal PCV13 IPD, 64.5% (43.7–77.6), 83.2% (73.7–89.3) and 85.1% (67.6–93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3–94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4–92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2–96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and −14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. Conclusions: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.
AB - Background: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010–11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). Methods: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012–2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. Results: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0–88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8–96.1) < 12 months to 85.1% (72.0–92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7–94.7) against fatal PCV13 IPD, 64.5% (43.7–77.6), 83.2% (73.7–89.3) and 85.1% (67.6–93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3–94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4–92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2–96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and −14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. Conclusions: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.
KW - 10-valent pneumococcal vaccine
KW - 13-valent pneumococcal vaccine
KW - Invasive pneumococcal disease
KW - Pneumococcal Infections
KW - Serotype
KW - Streptococcus pneumoniae
UR - http://www.scopus.com/inward/record.url?scp=85131385873&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.vaccine.2022.05.011
DO - https://doi.org/10.1016/j.vaccine.2022.05.011
M3 - Article
C2 - 35637067
SN - 0264-410X
VL - 40
SP - 3963
EP - 3974
JO - Vaccine
JF - Vaccine
IS - 29
ER -